DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Phase 2

Terminated

Conditions: Infection
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: caspofungin acetate
Drug: voriconazole

First Posted Date: 2005-10-13

Last Posted Date: 2025-04-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00238355

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: melphalan
Drug: thiotepa
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2005-10-13

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00238433

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2015-04-24

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00238199

Locations: 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Dietary Supplement: ascorbic acid
Drug: arsenic trioxide
Drug: dexamethasone
Drug: thalidomide

First Posted Date: 2005-09-28

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00227682

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer

Not Applicable

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Pain

Interventions: Other: placebo
Dietary Supplement: glutamine

First Posted Date: 2005-09-22

Last Posted Date: 2017-05-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00217724

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2017-05-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00182741

Locations: 🇺🇸
Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Not Applicable

Completed

Conditions: Malignant Glioma
Metastatic Malignant Neoplasm in the Brain
Central Nervous System Lymphoma

Interventions: Procedure: 3 Tesla Magnetic Resonance Imaging
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol
Drug: Gadolinium
Procedure: MRI-Based Angiogram

First Posted Date: 2005-02-08

Last Posted Date: 2022-06-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 155

Registration Number: NCT00103038

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Docetaxel in Treating Patients With Stage IV Prostate Cancer

Phase 2

Completed

Conditions: Pain
Prostate Cancer

First Posted Date: 2004-07-22

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00003781

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-06-17

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00004043

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Phase 2

Conditions: Malignant Glioma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Etoposide Phosphate
Other: Quality-of-Life Assessment
Drug: Sodium Thiosulfate

First Posted Date: 2004-01-12

Last Posted Date: 2022-05-03

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00075387

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy